# Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease

> **NCT01894594** · PHASE1 · TERMINATED · sponsor: **University Hospitals Cleveland Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Sickle Cell Anemia
- Chronic Kidney Disease
- Metabolic Acidosis

## Interventions

- **DRUG:** Sodium Bicarbonate

## Key facts

- **NCT ID:** NCT01894594
- **Lead sponsor:** University Hospitals Cleveland Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01894594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01894594, "Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01894594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*